ESGO17 Scientific programme

Saturday, November 4, 2017

ORAL COMMUNICATION: BEST ORAL PRESENTATIONS 1

09:30 - 10:30  Hall A

Chair: David Cibula (Czech Republic)
Chair: Heinz Koelbl (Austria)

09:30  TBC
 : TBC ()

09:45  AGO-OVAR 12: A RANDOMIZED PLACEBO-CONTROLLED GCIG/ENGOT-INTERGROUP PHASE III TRIAL WITH CHEMOTHERAPY +/- NINTEDANIB FOR ADVANCED OVARIAN CANCER: OVERALL SURVIVAL RESULTS
 : Isabelle Ray-Coquard (France)

10:00  CISPLATIN CHEMO-RADIATION VERSUS RADIATION IN FIGO STAGE IIIB SQUAMOUS CELL CARCINOMA OF THE UTERINE CERVIX (CRACX TRIAL: NCT00193791)
 : Umesh Mahantshetty (India)

10:15  CHANGES IN NEOANGIOGENETIC PROFILE OF PAIRED PRIMARY AND RECURRENT HIGH-GRADE SEROUS OVARIAN CANCER (HGOSC): A STUDY OF THE “OCTIPS” CONSORTIUM.
 : Ilary Ruscito (Italy)

PATIENTS PROGRAM: PATIENTS PROGRAM 1

10:00 - 17:00  Hall N

10:00  PATIENT SEMINAR WELCOME REMARKS - ESGO PRESIDENT, ENGAGE CO-CHAIR
David Cibula (Czech Republic)

10:10  PATIENT SEMINAR WELCOME REMARKS - ESGO PRESIDENT, ENGAGE CO-CHAIR
Murat Gultekin (Turkey)

10:15  COFFEE BREAK, MEET AND GREET

10:30  ROUNDTABLE DISCUSSIONS - WHAT IS NEW IN GYNAECOLOGICAL CANCERS?

10:31  TABLE 1 - OVARIAN CANCER
Jonathan Ledermann (United Kingdom)

10:31  TABLE 2 - CERVICAL CANCER
Francesco Raspagliesi (Italy)

10:31  TABLE 3 - VULVAR & VAGINAL CANCER
Sven Mahner (Germany)

10:31  TABLE 4 - UTERINE CANCER
Carien Creutzberg (The Netherlands)

12:00  LUNCH BREAK
13:00  **BLOCK 1**  
Chair: Cristiana Sessa (Switzerland)  
Chair: Birthe Lemley (Denmark)  
13:01  **WHAT IS A CLINICAL TRIAL? - DEVELOPMENT OF A NEW DRUG/NEW TREATMENT**  
Cristiana Sessa (Switzerland)  
13:15  **WHAT IS A CLINICAL TRIAL? - DEVELOPMENT OF A NEW DRUG/NEW TREATMENT**  
Birthe Lemley (Denmark)  
13:30  **DISCUSSION**  
13:35  **MANAGEMENT OF SURVIVORSHIP, ROLE OF REPEATED CONTROLS AND REHABILITATION**  
Heidi Donovan (USA)  
14:05  **HPV VACCINATION & SCREENING - WHAT IS IT, WHY IT IS IMPORTANT - HEALTH PROFESSIONALS VOICE, NGO'S VOICE, PATIENT’S VOICE.**  
14:06  **CERVICAL CANCER SCREENING WITH HPV DNA: UP TO DATE INFO FROM EUROPE**  
Murat Gultekin (Turkey)  
14:20  **HPV VACCINATION AND FUTURE OF CERVICAL CANCER IN EUROPE**  
Xavier Bosch (Spain)  
14:35  **WHY WE CAN? WHY WE CANNOT? ENGAGE PERSPECTIVE**  
Maude Anderssen (Sweden)  
14:50  **DISCUSSION**  
15:05  **COFFEE BREAK**  
15:30  **BLOCK 2:**  
Chair: Denis Querleu (France)  
Chair: Esra Urkmez (Turkey)  
15:31  **HOW CAN THE PATIENT EVALUATE QUALITY OF CARE?**  
Denis Querleu (France)  
15:50  **ENGAGE PERSPECTIVE**  
Birthe Lemley (Denmark)  
16:00  **NEW TREATMENT OPTIONS IN OVARIAN CANCER**  
Mansoor Raza Mirza (Denmark)  
16:40  **RECAP OF THE DAY**  
Esra Urkmez (Turkey)  

**STATE OF THE ART: HOT TOPICS IN FERTILITY SPARING MANAGEMENT**  
11:00 - 12:30  
Hall A  
Chair: Philippe Morice (France)  
Chair: Nicoletta Colombo (Italy)  
11:00  **FERTILITY SPARING MANAGEMENT IN HIGH RISK EPITHELIAL OVARIAN CANCER**  
Enrica Bentivegna (France)  
11:20  **CAN WE SAFELY USE OVARIAN HYPERSTIMULATION IN INFERTILE PATIENTS AFTER FSS FOR EPITHELIAL TUMORS?**  
Dominik Denschlag (Germany)  
11:40  **FERTILITY SPARING MANAGEMENT IN CERVICAL CANCERS BETWEEN 2 AND 4 CM: RADICAL TRACHELECTOMY BY LAPAROTOMY OR NEO-ADJUVANT CHEMOTHERAPY?**  
Ignace Vergote (Belgium)  
12:00  **HOW LONG SHOULD HORMONAL TREATMENT BE CONTINUED BEFORE DECIDING FOR HYSTERECTOMY IN THE FERTILITY SPARING MANAGEMENT OF ENDOMETRIAL
PARALLEL: IMAGING IN THE DIAGNOSIS AND MANAGEMENT OF GYNAECOLOGIC CANCER
11:00 - 12:30  Hall B

Chair: Ingfrid S. Haldorsen (Norway)
Chair: Christoph Grimm (Austria)
11:00  ENDOMETRIAL CANCER
Ingfrid S. Haldorsen (Norway)
11:20  CERVICAL CANCER
Daniela Fischerova, Ph.D. (Czech Republic)
11:40  OVARIAN CANCER
Christoph Grimm (Austria)
12:00  VULVA CANCER
Ate Van der Zee (The Netherlands)
12:20  DISCUSSION

PARALLEL: HPV - PREVENTION AND THERAPY
11:00 - 12:30  Hall C

Chair: Murat Gultekin (Turkey)
Chair: Elmar Joura (Austria)
11:00  PROPHYLACTIC AND THERAPEUTIC HPV VACCINATION: STATE OF THE ART
Elmar Joura (Austria)
11:20  HPV VACCINATION -THE UK EXPERIENCE
David Mesher (United Kingdom)
11:40  HPV PRIMARY SCREENING: IMPLEMENTATION OF THE FIRST NATIONAL PROGRAM WORLDWIDE
Murat Gultekin (Turkey)
12:00  COMPREHENSIVE HPV- CANCER PREVENTION OF THE FUTURE
Xavier Bosch (Spain)
12:20  DISCUSSION

WORKSHOP/SEMINAR: BASIC PRINCIPLES OF RECONSTRUCTION AFTER RADICAL PELVIC SURGERY: A PRACTICAL WORKSHOP
11:00 - 12:30  Hall M

Chair: Gwenaël Ferron (France)
Chair: Luis Chiva (Spain)
11:00  TIPS AND TRICKS FOR A SAFE CLOSURE AND RECONSTRUCTION OF THE ABDOMINAL WALL
Garcia-Urena Miguel Angel (Spain)
11:20  HOW TO SAFELY REBUILD THE URINARY TRACT  
Luis Chiva (Spain)
11:40  RECONSTRUCTIVE TECHNIQUES FOR VAGINAL AND PERINEAL DEFECTS  
Gwenaël Ferron (France)
12:00  BASIC PRINCIPLES OF BOWEL RECONSTRUCTION  
Roberto Biffi (Italy)
12:20  DISCUSSION

ENYGO SESSION: CAREER CORNER - MEET THE PROFESSOR

12:30 - 14:00  ENYGO LOUNGE

12:30  CAREER CORNER - MEET THE PROFESSOR'S  
Denis Querleu (France)
12:30  CAREER CORNER - MEET THE PROFESSOR'S  
Nadeem Abu Rustum (USA)
12:30  CAREER CORNER - MEET THE PROFESSOR'S  
Neville Hacker (Australia)

INDUSTRY SESSION : SATELLITE SYMPOSIUM 1

13:00 - 14:30  Hall B

ORAL COMMUNICATION: BEST ORAL PRESENTATIONS 2

14:30 - 15:30  Hall A

Chair: Christian Marth (Austria)  
Chair: Philippe Morice (France)
14:30  PRE-SURGICAL METFORMIN IN UTERINE MALIGNANCY-RESULTS OF THE PREMIUM RANDOMISED CONTROLLED TRIAL  
Sarah Kitson (United Kingdom)
14:45  THERAPEUTIC HPV VACCINE-IS IT CLINICALLY USEFUL?  
Jong Sup Park (Republic of Korea)
15:00  WHAT MODIFIES THE OUTCOME OF RECURRENT GRANULOSA CELL TUMORS OF THE OVARY?  
Isabel Carriles (Spain)
15:15  LION – LYMPHADENECTOMY IN OVARIAN NEOPLASMS. A PROSPECTIVE RANDOMIZED AGO STUDY GROUP LED GYNECOLOGIC CANCER INTERGROUP TRIAL.  
Domenica Lorusso (Italy)

STATE OF THE ART: PATHOLOGY - NEW AND UPDATED WHO 2014 CATEGORIES: WHAT THE CLINICIAN NEEDS TO KNOW
14:30 - 15:30  
Chair: Sigurd Lax (Austria)  
Chair: Glenn McCluggage (United Kingdom)  
14:30  
**CERVIX, VULVA, VAGINA**  
Glenn McCluggage (United Kingdom)  
14:50  
**OVARY AND FALLOPIAN TUBE**  
Xavier Matias-Guiu (Spain)  
15:10  
**UTERINE CORPUS**  
Sigurd Lax (Austria)  

**DEBATE: INTRAPERITONEAL CHEMOTHERAPY**  
14:30 - 15:30  
Chair: Charlie Gourley (United Kingdom)  
Chair: Andreas Du Bois (Germany)  
14:30  
**PRO SPEAKER**  
Charlie Gourley (United Kingdom)  
14:55  
**CON SPEAKER**  
Ignace Vergote (Belgium)  
15:20  
**DISCUSSION**  

**TASK FORCE: EOTTD**  
14:30 - 15:30  
Chair: François Golfier (France)  
Chair: Frederic Goffin (Belgium)  
14:30  
**EOTTD GUIDELINES FOR HYDATIDIFORM MOLES AND GTN**  
Frederic Goffin (Belgium)  
14:50  
**IS THERE A PLACE FOR A SECOND CURETTAGE IN GTD?**  
Nienke Van Trommel (The Netherlands)  
15:10  
**HYSTERECTOMY IN GTN: AN EFFICIENT ROLE IN OLDER WOMEN?**  
François Golfier (France)  

**PARALLEL: UP-DATE ON SENTINEL LYMPH NODE IN GYNAECOLOGICAL TUMORS**  
16:00 - 17:00  
Chair: David Cibula (Czech Republic)  
Chair: Eric Leblanc (France)  
16:00  
**DEVELOPMENTS IN DETECTION TECHNIQUES**  
Eric Leblanc (France)
16:20  SLN IMPLEMENTATION INTO MANAGEMENT ALGORITHMS  
Nadeem Abu Rustum (USA)

16:40  QUESTIONS REMAINED TO BE ANSWERED  
David Cibula (Czech Republic)

PARALLEL: MYTHS AND FACTS ABOUT LIQUID BIOPSIES
16:00 - 17:00  Hall B

Chair: Adriaan Vanderstichele (Belgium)
Chair: Heidi Fiegl (Austria)

16:00  WHOLE-GENOME SEQUENCING OF CELL-FREE DNA IN GYNAECOLOGICAL CANCERS  
Adriaan Vanderstichele (Belgium)

16:20  DETECTION OF METHYLATED DNA IN VARIOUS BODY FLUIDS AND THEIR USE AS DIAGNOSTIC, PROGNOSTIC AND PREDICTIVE TOOLS IN GYNAECOLOGICAL CANCERS  
Heidi Fiegl (Austria)

16:40  CIRCULATING TUMOR CELLS: CHALLENGES & PERSPECTIVES IN GYNAECOLOGICAL CANCERS  
Catherine Alix-Panabieres (France)

ORAL COMMUNICATION: ORAL 1 - OVARIAN
16:00 - 17:00  Hall C

Chair: Alexandra Leary (France)
Chair: Paul Sevelda (Austria)

16:00  RANDOMIZED CONTROLLED PHASE III STUDY TO EVALUATE SECONDARY CYTOREDUCTIVE SURGERY IN PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER - AGO DESKTOP III/ENGOT OV20  
: Jalid Sehouli (Germany)

16:10  PATTERNS OF LYMPH NODE METASTASES IN APPARENT STAGE I LOW-GRADE EPITHELIAL OVARIAN CANCER: A MULTICENTER STUDY.  
: Lucas Minig (Spain)

16:20  MUCINOUS OVARIAN CANCER (MOC) : WHAT IS THE REPRODUCIBILITY OF THE WHO CLASSIFICATION ?  
: Catherine Genestie (France)

16:30  THE ROLE OF THE PERITONEAL CANCER INDEX IN SURGERY FOR ADVANCED OVARIAN CANCER  
: Mikkel Rosendahl (Denmark)

16:40  THE PERITONEAL CANCER INDEX(PCI): SELTED REGIONS - AND NOT THE TOTAL PCI - ARE PREDICTIVE OF SURVIVAL IN ADVANCED OVARIAN CANCER  
: Mikkel Rosendahl (Denmark)

16:50  HORMONAL AND FERTILITY OUTCOME AFTER FERTILITY SPARING SURGERY AND CHEMOTHERAPY FOR OVARIAN NEOPLASMS: A RETROSPECTIVE STUDY  
: Lorenzo Ceppi (Italy)
ORAL COMMUNICATION: ORAL 2 - CERVIX

16:00 - 17:00 Hall M

Chair: Alexander Reinthaller (Austria)
Chair: Christine Haie-Meder (France)

16:00 DECISIONAL VALUE OF PRETHERAPEUTIC LAPAROSCOPIC EXTRAPERITONEAL ILIO-PARAORTIC (EL-PALND) VERSUS PET-CT IN LOCALLY ADVANCED CERVICAL CARCINOMAS (LACC)
  : Eric Leblanc (France)

16:10 NATURAL HISTORY OF CERVICAL INTRAEPITHELIAL NEOPLASIA GRADE 2 UNDER ACTIVE SURVEILLANCE – A SYSTEMATIC REVIEW AND META-ANALYSIS
  : Karoliina Tainio (Finland)

16:20 CERVICAL CANCER RELAPSE RATES IN PATIENTS WITH PARA-AORTIC NEGITIVE PET SCANS: A FIVE-YEAR ANALYSIS IN AN IRISH GYNAEONCOLOGY CENTRE
  : Ann Rowan (Ireland)

16:30 IMPACT OF ADJUVANT HysterECTOMY ON PROGNOSIS IN PATIENTS WITH LOCALLY ADVANCED CERVICAL CANCER TREATED WITH DEFINITIVE CONCURRENT CHEMORADIOTHERAPY: A META-ANALYSIS
  : Seung-Hyuk Shim (Republic of Korea)

16:40 ONCOLOGICAL AND OBSTETRIC OUTCOME OF ABDOMINAL RADICAL TRACHELECTOMY (ART): AN UPDATED SERIES OF CERVICAL CANCER FROM A 13-YEAR EXPERIENCE
  : Xiaohua Wu (China)

16:50 OUTCOMES OF ROBOTIC RADICAL HYSTERECTOMY FOR CERVICAL CANCER IN COMPARISON TO OPEN AND LAPAROSCOPIC CASES; A POPULATION BASED STUDY IN THE UNITED STATES
  : Sabrina Piedimonte (Canada)

INDUSTRY SESSION : SATELLITE SYMPOSIUM 2

17:00 - 18:00 Hall A

NETWORKING EVENTS: OPENING CEREMONY (FOLLOWED BY WELCOME RECEPTION IN EXHIBITION)

18:00 - 18:30 Hall A

Chair: Nadia Mader-Mueller (Austria)
Chair: David Cibula (Czech Republic)
Chair: Heinz Koelbl (Austria)

06:00 WELCOME FROM ESGO PRESIDENT
  David Cibula (Czech Republic)
06:05  WELCOME FROM CONGRESS PRESIDENT
       Heinz Koelbl (Austria)
06:10  WELCOME FROM RECTOR OF MEDICAL UNIVERSITY OF VIENNA
       Marcus Mueller (Austria)
06:15  THE ROLE OF CENTRAL EUROPE IN THE PAST, THE PRESENCE AND THE FUTURE
       Karl Habsburg (Austria)
06:35  SINFONIA ACADEMICA

OFFSITE SESSION: FROM HYSTERIA TO PSYCHO-ONCOLOGY

20:00 - 22:00  Sig. Freud Museum

   Chair: Annette Hasenburg (Germany)
20:00  GUIDED TOUR
20:30  Luzia Travado (Portugal)
21:15  Elisabeth Andritsch (Austria)

Sunday, November 5, 2017

WORKSHOP: COLPOSCOPY WORKSHOP

07:30 - 08:30  Hall C

   Chair: Vesna Kesic (Serbia)
   Chair: Alexander Reinthaller (Austria)
07:30  QUALITY INDICATORS FOR COLPOSCOPY
       Elmar Joura (Austria)
07:50  OBJECTIFYING COLPOSCOPIC FINDINGS: CRITERIA AND NEW TECHNOLOGIES
       Vesna Kesic (Serbia)
08:10  POSITIVE CERVICAL CYTOLOGY AND/OR HIGH RISK HPV INFECTION -
       COLPOSCOPIC ASSESSMENT AND CLINICAL MANAGEMENT
       Alexander Reinthaller (Austria)

VIDEO SESSION: INNOVATIVE SURGICAL PROCEDURES IN GYNAECOLOGICAL ONCOLOGY

07:30 - 08:30  Hall B

   Chair: Francesco Raspagliesi (Italy)
   Chair: Alexandros Rodolakis (Greece)
07:30 ROBOTIC EXPERT VIDEO
Rainer Kimmig (Germany)

07:40 INDOCYANINE-GREEN (ICG) LABELING FOR COMPARTMENT-BASED ROBOTIC RADICAL SURGERY IN EARLY CERVICAL CANCER
Carlo Ronsini (Italy)

07:50 LAPAROSCOPIC SURGERY VIDEO
Francesco Raspagliesi (Italy)

08:00 UTERINE TRANSPOSITION SURGICAL TECHNIQUE
Reitan Ribeiro (Brazil)

08:10 OPEN SURGERY VIDEO
Alexandros Rodolakis (Greece)

08:20 SECONDARY DEBULKING SURGERY FOR ISOLATED PARA-AORTIC NODAL RECURRENT IN OVARIAN CANCER INVOLVING RENAL MOBILIZATION
Kazuyoshi Kato (Japan)

PATIENTS PROGRAM: PATIENTS PROGRAM 2

08:15 - 13:40 Hall N

Chair: Elisabeth Avall-Lundqvist (Sweden)
Chair: Dina Kurdiani (Georgia)

08:15 LATE EFFECTS OF TREATMENT INCL. LYMPHEDEMA

08:16 RADIOTHERAPY
Richard Poetter (Austria)

08:30 SURGERY
Jalid Sehouli (Germany)

09:00 CHEMOTHERAPY
Elisabeth Avall-Lundqvist (Sweden)

09:15 ENGAGE PERSPECTIVES
Maria Papageorgiou (Georgia)

09:30 PRESIDENTIAL ADDRESS - MAIN HALL

10:30 COFFEE BREAK

10:40 ROUNDTABLE DISCUSSION - LET THE EXPERT NGOS SPEAK

10:41 TABLE 1 - POLICY ADVOCACY
Simona Ene (Romania)

10:41 TABLE 2 - HOW TO GET DRS INVOLVED WITH NGOS - DANCE WITH CANCER SPEAKER
TBA TBA ()

10:41 TABLE 3 - WORKING WITH ESGO - PRESIDENT (2017-2019)
Denis Querleu (France)

10:41 TABLE 3 - WORKING WITH ESGO - VICE PRESIDENT ELECT (2017-2019)
Cristiana Sessa (Switzerland)

11:40 FEEDBACK FROM MEMBERS
Chair: Esra Urkmez (Turkey)
Chair: Murat Gultekin (Turkey)

12:40 ENGAGE GENERAL ASSEMBLY

PARALLEL: THE MANAGEMENT OF VULVA CANCER: ESGO GUIDELINES

08:30 - 09:30 Hall A
DIAGNOSIS, STAGING AND PREOPERATIVE WORKUP
Maaike.H.M. Oonk (The Netherlands)

SURGERY AND ADJUVANT THERAPY IN PRIMARY DISEASE
Sven Mahner (Germany)

TREATMENT OF RECURRENT AND METASTATIC DISEASE
Ate Van der Zee (The Netherlands)

PARALLEL: MULTIDISCIPLINARY TREATMENT OF GYNE CANCERS IN ADOLESCENTS

INTRODUCTION
Cristiana Sessa (Switzerland)

CASE PRESENTATION 1: STAGE I GRADE 3 IMMATURE TERATOMA
Gabriele Calaminus (Germany)

CASE PRESENTATION 2: SERTOLI LEYDIG CELL TUMOR
Dominik Schneider (Germany)

SUMMARY AND CONCLUSIONS
Gabriele Calaminus (Germany)

HOW TO IMPROVE SENTINEL LYMPH NODE MAPPING WITH INDOCYANINE GREEN (ICG) IN ENDOMETRIAL CANCER?
Noémie Body (Canada)

REFINEMENT OF HIGH-RISK ENDOMETRIAL-CANCER (HR-EC) CLASSIFICATION USING DNA DAMAGE RESPONSE (DDR) BIOMARKERS: A TRANSPORTEC INITIATIVE
Aurélie Auguste (France)

IMPACT OF CONSERVATIVE MANAGEMENTS IN YOUNG WOMEN WITH GRADE 2 OR 3 ENDOMETRIAL ADENOCARCINOMA CONFINED TO ENDOMETRIUM
Martin Koskas (Belgium)

ULTRASOUND CHARACTERISTICS OF ENDOMETRIAL CANCER AS DEFINED BY THE INTERNATIONAL ENDOMETRIAL TUMOR ANALYSIS (IETA) CONSENSUS NOMENCLATURE- A PROSPECTIVE MULTICENTER STUDY
Daniela Fischerova, Ph.D. (Czech Republic)
09:10  THE EFFECT OF HYSTERECTOMY ON PELVIC FLOOR SYMPTOMS
: Andreas Obermair (Australia)

09:20  FRENCH MULTICENTRIC RANDOMIZED TRIAL EVALUATING SEVERE
PERIOPERATIVE MORBIDITY AFTER ROBOT ASSISTED VERSUS CONVENTIONAL
LAPAROSCOPY IN GYNECOLOGIC ONCOLOGY: RESULTS OF ROBOGYN TRIAL.
: Fabrice Narducci (France)

PARALLEL: PHASE I / II TRIALS: THE ENGOT STRATEGY

08:30 - 09:30  Hall M

Chair: Nicole Concin (Austria)
Chair: Ignace Vergote (Belgium)

08:30  ENGOT PHASE I/II TRIALS: INTRODUCTION OF THE NEW GROUP
Nicole Concin (Austria)

08:50  A NEW CONCEPT OF UMBRELLA PHASE I/II TRIALS
Mansoor Raza Mirza (Denmark)

09:10  FUTURE DIRECTIONS OF INTERESTING COMPOUNDS FOR EARLY CLINICAL
TESTING
Antonio Casado (Spain)

POSTER SESSION: PALLIATIVE CARE

08:30 - 18:00  Exhibition Area

PALLIATIVE PELVIC EXENTERATION – A SINGLE INSTITUTION EXPERIENCE AND
OUTCOMES IN CERVICAL AND VAGINAL CANCER
O. Akbayır, S.C. Ulukent, E. Canaz, E.S. Ozyürek, B. Erdem, B. Ozköse, O. Aşıcıoğlu, Y.
Ozgün, A. Akça (Turkey)

IS THERE TIMELY INTERVENTION OF PALLIATIVE CARE IN GYNAECOLOGICAL
CANCER PATIENTS AT THE END OF LIFE?
N. Rahim, S. Kauschik (United Kingdom)

THE RELATIONSHIP BETWEEN SYMPTOM BURDEN, BODY IMAGE AND QUALITY OF
LIFE IN ASIAN GYNAECOLOGICAL CANCER PATIENTS
K. Tewani, Y. Lim, I. Teo (Singapore)

PLENARY: PRESIDENTIAL ADDRESS

09:30 - 10:30  Hall A

Chair: Luis Chiva (Spain)

09:30  INTRODUCTION
Luis Chiva (Spain)

09:35  ESGO – A STORY OF SUCCESS
David Cibula (Czech Republic)
STATE OF THE ART: NEW ESGO-ESTRO-ESP GUIDELINES ON CERVICAL CANCER MANAGEMENT
11:00 - 12:30  
Hall A

Chair: David Cibula (Czech Republic)  
Chair: Richard Poetter (Austria)  
Chair: Maria-Rosaria Raspollini (Italy)  
11:00  
SHAPING NEW CLINICAL PRACTICE GUIDELINES  
David Cibula (Czech Republic)  
11:15  
PATHOLOGY REPORT  
Maria-Rosaria Raspollini (Italy)  
11:30  
MANAGEMENT OF EARLY STAGES  
David Cibula (Czech Republic)  
12:00  
MANAGEMENT OF ADVANCED STAGES AND RECURRENT DISEASE  
Richard Poetter (Austria)  

PARALLEL: NOVEL CONCEPTS OF PERIOPERATIVE MANAGEMENT
11:00 - 12:30  
Hall B

Chair: Stephanie Suria (France)  
Chair: Karl Tamussino (Austria)  
11:00  
INITIATING ENHANCED RECOVERY: CHALLENGES AND OPPORTUNITIES  
Lena Wijk (Sweden)  
11:22  
WHAT’S NEW IN ANESTHESIA FOR HIGH-RISK PATIENTS: WHAT SURGEONS NEED TO KNOW  
Stephanie Suria (France)  
11:45  
BOWEL PREPARATION AND CARBO LOADING: WHAT IS THE CURRENT EVIDENCE?  
Lausanne Chahin Achtari (Switzerland)  
12:07  
PERIOPERATIVE CARE OF THE ELDERLY PATIENT  
Karl Tamussino (Austria)  

PARALLEL: BREAST CANCER: AN UPDATE
11:00 - 12:30  
Hall C

Chair: Christine Solbach (Germany)  
Chair: Edgar Petru (Austria)  
11:00  
NEoadjuvant Chemo- and AntiHormonal Therapy: New Targets, Pathological Response and Future Perspectives  
Edgar Petru (Austria)  
11:22  
Major Changes in Surgical Therapy for Breast Cancer  
Christine Solbach (Germany)  
11:45  
Adjuvant Systemic Chemotherapy: Who Does Not Need It - Who Needs Dose Dense Therapy?  
Christian Jackisch (Germany)  
12:07  
Adjuvant Endocrine Therapy - The Longer The Better?  
Mitch Dowsett (United Kingdom)
PARALLEL: YOUNG INVESTIGATORS

11:00 - 12:30

Chair: Kamil Zalewski (Poland)
Chair: Kristina Lindemann (Norway)

11:00 ACCURACY OF PRE-OPERATIVE GRADING BY PIPELLE ENDOOMETRIAL SAMPLING AND DILATATION AND CURETTAGE IN ENDOOMETRIAL CANCER
: Ho Sze Jacqueline Lee (Hong Kong S.A.R.)

11:08 COMPLIANCE TO ADJUVANT TREATMENT GUIDELINES IN ENDOOMETRIAL CANCER: ROOM FOR IMPROVEMENT IN HIGH RISK PATIENTS
: Florine Eggink, Drs. (The Netherlands)

11:16 PROTEOMIC PROFILING OF ENDOMETRIOID ENDOOMETRIAL CANCER REVEALS DIFFERENTIAL EXPRESSION OF HORMONE RECEPTORS AND MAPK SIGNALING PROTEINS IN OBESE VERSUS NON-OBESE PATIENTS
: Karen Klepsland Mauland (Norway)

11:24 VULVAR PAGET DISEASE IN THE NETHERLANDS
: Michelle Van der Linden (The Netherlands)

11:32 RISK PREDICTION OF SEVERE POSTOPERATIVE COMPLICATIONS IN PATIENTS UNDERGOING GYNECOLOGIC CANCER SURGERY: RESULTS OF A PROSPECTIVE STUDY IN 237 PATIENTS
: Gülhan Inci (Germany)

11:40 CLINICAL CHARACTERISTICS AND GENOMIC BIOMARKERS OF THE HOMOLOGOUS RECOMBINATION DEFICIENCY PHENOTYPE IN HIGH-GRADE SEROUS OVARIAN CANCER
: Katrien Nulens (Belgium)

11:48 RELIABILITY OF SLN BIOPSY IN PATIENTS WITH BULKY CERVICAL CANCER
: Lukas Dostalek (Czech Republic)

11:56 IDENTIFICATION OF PROTEIN MARKERS OF PROGRESSION RISK IN PATIENTS WITH SQUAMOUS CELL VULVAR CARCINOMA
: Magdalena Kowalewska (Poland)

12:04 THE ACCURACY OF FROZEN SECTION OF UTERINE LESIONS IN THE PRACTICE OF GYNECOLOGIC SURGERY. A RETROSPECTIVE ASSESSMENT STUDY IN A GOVERNMENT TERTIARY TRAINING HOSPITAL
: Jimmy Billod (Philippines)

12:12 ANALYSIS OF PATIENTS WITH CYTOLOGY NEGATIVE AND HPV 16/18 POSITIVE ON CERVICAL CANCER SCREENING PROGRAM: EXPERIENCE FROM A SINGLE CENTER IN EASTERN REGION OF TURKEY
: Erbil Karaman (Turkey)

12:20 SURGICAL CYTOREDUCTION OF THE UPPER ABDOMEN IN GYNAECOLOGICAL CANCER: AN EXPERIENCE OF ADDITIONAL SKILL ACQUISITION BY THE GYNAECOLOGY ONCOLOGY TEAM FROM COLLABORATION WITH HEPATOBILIARY SURGEONS
: Saurabh Phadnis (United Kingdom)

ENYGO SESSION: ENYGO/ESGO PROPOSALS FOR TRAINEES

12:30 - 14:00

12:30 ENYGO/ESGO PROPOSALS FOR TRAINEES
12:40 - ESTROGEN RECEPTOR AND PROGESTERONE RECEPTOR DOUBLE NEGATIVITY PREDICTS POOR SURVIVALS IN PATIENTS WITH GRADE I AND II ENDOMETRIAL ADENOCARCINOMA
J. Guan, L.Y. Xie, Q. Zhu, X.J. Chen (China)

12:45 - COMPARISON OF UTERINE LEIOMYOSARCOMA (LMS) AND LEIOMYOMA (LM) FINDINGS FOR CREATION OF A PREOPERATIVE LMS-RISK-SCORE
D. Trojnarska, M. Köller, C. Riechmann, J. Kirchbaum, H. Lehnhoff, A. Marcinek, M. Franze, M. Zygmunt, G. Köhler (Germany)

12:50 - EXPRESSION OF miR-146a IN PRIMARY TUMOUR AND OMENTAL IMPLANTS IN OVARIAN CANCER PATIENTS AND ITS CORRELATION WITH CLINICOPATHOLOGICAL FEATURES, PROGNOSIS AND CHEMO-RESISTANCE
M. Wilczyński, E. Zytko, B. Szymańska, M. Dziegielewska, J. Danielska (Poland)

12:55 - A panel of microRNAs, identified with global microarray, may provide prognostic information for patients with ovarian cancer
K.P. Prahm (Denmark)

13:00 - ROBOTIC VERSUS LAPAROSCOPIC TRANSPERITONEAL PARAAORTIC LYMPHADENECTOMY IN GYNECOLOGIC CANCERS: A SINGLE INSTITUTE EXPERIENCE
V. Gallotta, K. Gaballa, C. Conte, A. Federico, A. Biscione, M.T. Giudice, S. Pelligra, V. Chiantera, G. Vizziielli, S. Gueli Alletti, A. Fagotti, G. Scambia, M.G. Ferrandina (Egypt)

13:05 - OPTICAL IMAGING FOR PERITONEAL METASTASES DETECTION IN OVARIAN CANCER: A PILOT STUDY
F.C. Pop, I. Veys, S. Vankercikhove, R. Barbieux, M. Gomez Caldon, M. Moreau, D. Larsimont, V. Donckier, P. Bourgeois, G. Liberale (Belgium)

13:10 - PRIMA-1MET INDUCES APOPTOSIS THROUGH ACCUMULATION OF INTRACELLULAR REACTIVE OXYGEN SPECIES IRRESPECTIVE OF P53 STATUS AND CHEMO-SENSITIVITY IN EPITHELIAL OVARIAN CANCER CELLS
N. Yoshikawa, Y. Shimizu, M. Yoshihara, K. Nakamura, S. Suzuki, H. Kajiyama, F. Kikikawa (Japan)

13:15 - GENOMIC LANDSCAPE OF BRAIN METASTASIS FROM OVARIAN/PERITONEAL CANCER
H.J. Kang, J.S. Park, S.Y. Hur, Y.J. Choi (Republic of Korea)

13:20 - COMPARISON OF GENE MUTATIONAL ANALYSES, INCLUDING BRCA1 ALTERATIONS, IN TWO PROSPECTIVE STUDIES IN NEWLY DIAGNOSED VERSUS PLATINUM-RESISTANT OVARIAN CANCER

13:25 - SYMPTOMS RELEVANT TO SURVEILLANCE FOR OVARIAN CANCER
E. Pavlik, R. Ore (USA)
STATE OF THE ART: ENDOMETRIAL CANCER

14:30 - 15:30  
Hall A

Chair: Carien Creutzberg (The Netherlands)  
Chair: Frederic Goffin (Belgium)

14:30 DIAGNOSTIC AND SURGICAL MANAGEMENT  
Frederic Goffin (Belgium)

14:50 ADJUVANT TREATMENT  
Carien Creutzberg (The Netherlands)

15:10 TREATMENT OF ADVANCED DISEASE, INCLUDING MANAGEMENT OF MORBIDITY  
Alexandra Taylor (United Kingdom)

PARALLEL: SEXUAL HEALTH AFTER CANCER DIAGNOSIS AND FOLLOWING TREATMENT

14:30 - 15:30  
Hall B

Chair: Kathrin Kirchheiner (Austria)  
Chair: Diethelm Wallwiener (Germany)

14:30 SEXUAL HEALTH IN GYNAECOLOGIC CANCER PATIENTS - PSYCHO-SOCIAL CONSEQUENCES OF DIAGNOSIS AND TREATMENT  
Moniek M Ter Kuile (The Netherlands)

14:50 PHYSICAL CONSEQUENCES OF GYNAECOLOGIC CANCER SURGERY AND THEIR IMPACT ON SEXUAL HEALTH  
Michal Zikan (Czech Republic)

15:10 IMPACT OF VAGINAL MORBIDITY ON SEXUALITY AFTER DEFINITIVE RADIOCHEMOTHERAPY IN LOCALLY ADVANCED CERVICAL CANCER PATIENTS  
Kathrin Kirchheiner (Austria)

TASK FORCE: ENGAGE: A COLLABORATION BETWEEN PATIENT ADVOCACY GROUPS AND ESGO

14:30 - 15:30  
Hall C

Chair: Murat Gultekin (Turkey)  
Chair: Esra Urkmez (Turkey)

14:30 POWER OF BEING VISIBLE: MEDIA, NGOS AND AWARENESS ACTIVITIES  
Murat Gultekin (Turkey)

14:35 THE OTHER SIDE OF THE COIN: PATIENT STORIES INCLUDING LADY GANGA STORY  
Esra Urkmez (Turkey)

15:00 THE OTHER SIDE OF THE COIN: WHAT THE PATIENTS WANT TO TELL TO THEIR DOCTOR – RESULT FROM A SURVEY, INTERACTIVE  
Esra Urkmez (Turkey)

15:20 HOW CAN THE PATIENTS EVALUATE THE QUALITY OF CARE  
Denis Querleu (France)
ORAL COMMUNICATION: ORAL 4 - OVARIAN II

14:30 - 15:30  Hall M

Chair: Annamaria Ferrero (Italy)
Chair: Christoph Grimm (Austria)

14:30  PERIOPERATIVE POSITIONING MANAGEMENT IN GYNECOLOGIC CANCER SURGERY: A NATIONAL NOGGO-AGO INTERGROUP SURVEY
: Jenny Katharina Wagner (Germany)

14:40  What are the expectations and preferences of patients with ovarian cancer to a maintenance therapy? A NOGGO/ENGOT-ov22 survey (Expression IV) in 2101 patients.
: Irena Rohr (Germany)

14:50  ADVERSE EVENTS AFTER HYPERThERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) FOR STAGE III OVARIAN CANCER: PHASE III OvHIPEC STUDY
: Simone Koole (The Netherlands)

15:00  IDENTIFICATION OF HIGHLY DIFFERENTIALLY EXPRESSED GENES IN PRIMARY OVARIAN CANCER AND RELATED DISTANT METASTASIS USING RNA SEQUENCING
: Hanna Sallinen (Finland)

15:10  INTERVAL BETWEEN CYTOREDUCTIVE SURGERY AND ADJUVANT CHEMOTHERAPY IS ASSOCIATED WITH OVERALL SURVIVAL IN PATIENTS WITH ADVANCED OVARIAN CANCER
: Maite Timmermans, MD (The Netherlands)

15:20  PALB2 MUTATIONS IN HIGH-RISK WOMEN WITH OVARIAN OR BREAST CANCER
: Kelly Metcalfe (Canada)

INDUSTRY SESSION: SATELLITE SYMPOSIUM 4

16:00 - 17:00  Hall A

INDUSTRY SESSION: SATELLITE SYMPOSIUM 5

16:00 - 17:00  Hall B

PARALLEL: FUTURE BRACHYTHERAPY CHALLENGES IN THE MANAGEMENT OF ADVANCED CERVICAL CANCER

17:00 - 18:00  Hall A
Chair: Jacob Lindegaard (Denmark)
Chair: Akila Viswanathan (India)
Chair: Christine Haie-Meder (France)

17:00 CURRENT STATUS OF IMAGE-GUIDED BRACHYTHERAPY: ONCOLOGICAL RESULTS AND COMPLICATIONS
Jacob Lindegaard (Denmark)

17:20 IMAGE-GUIDED ADAPTIVE BRACHYTHERAPY VERSUS IMRT/STEREOTACTIC RADIOTHERAPY
Akila Viswanathan (India)

17:40 GENERAL IMPLEMENTATION OF IGABT (TRAINING/MEANS/HEALTH ECONOMICS/RESOURCE LIMITATIONS)
Christine Haie-Meder (France)

PARALLEL: WHEN, WHY AND HOW TO TEST MOLECULAR BIOMARKERS IN ENDOMETRIAL CANCER
17:00 - 18:00 Hall B

Chair: Alain G. Zeimet (Austria)
Chair: Tjalling Bosse (The Netherlands)

17:00 WHEN, WHY AND HOW TO TEST POLE MUTATIONAL STATUS IN ENDOMETRIAL CANCER
David Church (United Kingdom)

17:20 WHEN, WHY AND HOW TO TEST FOR L1CAM AND P53 EXPRESSION IN ENDOMETRIAL CANCER
Alain G. Zeimet (Austria)

17:40 WHEN, WHY AND HOW TO TEST MISMATCH REPAIR DEFICIENCY IN ENDOMETRIAL CANCER
Tjalling Bosse (The Netherlands)

ORAL COMMUNICATION: ORAL 5 - VAGINAL AND VULVAR CANCER
17:00 - 18:00 Hall C

Chair: Maaike.H.M. Oonk (The Netherlands)
Chair: Sven Mahner (Germany)

17:00 PROGNOSTIC VALUE OF LYMPH NODE RATIO AND NUMBER OF POSITIVE INGUINAL NODES IN PATIENTS WITH VULVAR CANCER
: Richard Schwameis (Austria)

17:10 PROGNOSTIC FACTORS FOR LOCAL RECURRENCE OF SQUAMOUS CELL CARCINOMA OF THE VULVA: A SYSTEMATIC REVIEW
: Nienke Te Grootenhuis (The Netherlands)

17:20 VULVAR CANCER IN IRELAND: ANALYSIS OF THE IRISH NATIONAL CANCER REGISTRY OVER A 20 YEAR PERIOD
: Ann Rowan (Ireland)

17:30 VULVAR CARCINOMA IN NORWAY: A 50-YEAR PERSPECTIVE ON TRENDS IN INCIDENCE, TREATMENT AND SURVIVAL
: Christin Julia Meltzer-Gunnes (Norway)
17:40 EXPERIENCE IN INTRODUCING SENTINEL LYMPH NODE BIOPSY IN EARLY-STAGE VULVA CANCER: A SINGLE INSTITUTION BASED PROSPECTIVE STUDY
: Ligita Paskeviciute Frøding (Denmark)

17:50 INCIDENCE OF SHORT AND LONG-TERM POSTOPERATIVE MORBIDITY RELATED TO LYMPH NODE DISSECTION FOR VULVAR CANCER
: Ellen Barlow (Australia)

AFFILIATED: IPOS-ESGO: BODY AND SOUL

17:00 - 18:30 Hall M

   Chair: Vesna Kesic (Serbia)

17:00 NEUROCOGNITIVE DYSFUNCTION AFTER CHEMOTHERAPY: PREVALENCE AND TREATMENT (IPOS)
: Joachim Weis (Germany)

17:22 CHALLENGES FOR PREGNANT WOMEN DIAGNOSED WITH CANCER (ESGO)
: Tineke Vandenbroucke (Belgium)

17:44 WHY DOES PSYCHOSOCIAL CARE MATTER FOR CANCER PATIENTS? (IPOS)
: Luzia Travado (Portugal)

18:06 LIFE AFTER CANCER - THE NEW ME (ESGO)
: Annette Hasenburg (Germany)

Monday, November 6, 2017

PARALLEL: PLATINUM RESISTANCE: A CHALLENGE IN OVARIAN CANCER TREATMENT

07:30 - 08:30 Hall B

   Chair: Mansoor Raza Mirza (Denmark)
   Chair: Nicole Concin (Austria)

07:30 PLATINUM-RESISTANT DISEASE: CURRENT STATUS
: Nicole Concin (Austria)

07:50 STRATEGIES FOR OVERCOMING RESISTANCE TO CHEMOTHERAPY
: Sandro Pignata (Italy)

08:10 CLINICAL TRIALS IN PLATINUM-RESISTANT DISEASE
: Mansoor Raza Mirza (Denmark)

VIDEO SESSION: SURGERY OF OVARIAN CANCER

07:30 - 08:30 Hall C

   Chair: Rene Laky (Austria)
   Chair: Jordi Ponce (Spain)
07:30  STANDARD SURGICAL STAGING OF EARLY OVARIAN CANCER
        Jordi Ponce (Spain)
07:50  ADVANCED OVARIAN CANCER: PELVIC CYTOREDUCTION
        Rene Laky (Austria)
08:10  ADVANCED OVARIAN CANCER: UPPER ABDOMINAL AND EXTENDED
        CYTOREDUCTION
        Cagatay Taskeran (Turkey)

PARALLEL: TARGETED THERAPIES FOR BRCA1/2 MUTATED TUMORS

08:30 - 09:30  

Chair: Cristiana Sessa (Switzerland)
Chair: Iain McNeish (United Kingdom)

08:30  UPDATE ON THE CLINICAL DEVELOPMENT OF PARP INHIBITORS
        Iain McNeish (United Kingdom)
08:50  CLINICAL DEVELOPMENT OF OTHER NON PARP Targeted Therapies
        Cristiana Sessa (Switzerland)
09:10  MECHANISMS OF RESISTANCE IN BRCA MUTATED TUMORS
        Clare Scott (Australia)

ORAL COMMUNICATION: LBO1

08:30 - 09:30  

08:30  PLACE OF SURGERY FOR RELAPSED GERM CELL TUMORS?
        Nicoletta Colombo (Italy)
08:45  CONSERVATIVE SURGERY FOR OVARIAN SMALL CELL CARCINOMA, A PLACE?
        Philippe Morice (France)
09:00  SYSTEMATIC TREATMENT FOR NON-Epithelial Tumor
        Isabelle Ray-Coquard (France)
09:15  SYSTEMATIC TREATMENT FOR EPITHELIAL RARE TUMORS
        Jonathan Ledermann (United Kingdom)

ORAL COMMUNICATION: ORAL 6 - PREVENTION, DIAGNOSTICS AND PREINVASIVE DISEASE

08:30 - 09:30  

08:30  PLACE OF SURGERY FOR RELAPSED GERM CELL TUMORS?
        Nicoletta Colombo (Italy)
08:45  CONSERVATIVE SURGERY FOR OVARIAN SMALL CELL CARCINOMA, A PLACE?
        Philippe Morice (France)
09:00  SYSTEMATIC TREATMENT FOR NON-Epithelial Tumor
        Isabelle Ray-Coquard (France)
09:15  SYSTEMATIC TREATMENT FOR EPITHELIAL RARE TUMORS
        Jonathan Ledermann (United Kingdom)
08:30  STATHMIN, A PREDICTIVE BIOMARKER FOR TAXANE RESPONSE IN BREAST CANCER?
        : Erica Werner ()

08:40  MRI-BASED PREDICTIVE FACTORS OF AXILLARY LYMPH NODE METASTASES IN BREAST CANCER
        : David Atallah (Lebanon)

08:50  CLINICAL CHARACTERISTICS AND PROGNOSIS OF ULTRA HIGH-RISK GESTATIONAL TROPHOBLASTIC NEOPLASIA PATIENTS: A RETROSPECTIVE COHORT STUDY
        : Yujia Kong (China)

09:00  PATTERNS OF CARE AND THE SURVIVAL OF ELDERLY PATIENTS WITH HIGH-RISK ENDOMETRIAL CANCER: A CASE-CONTROL STUDY FROM THE FRANCOGYN GROUP
        : Vincent Lavoue, MD, PhD (France)

09:10  POTENTIAL CLINICAL IMPACT OF THE INTRODUCTION OF THE NONAVALENT HUMAN PAPILLOMAVIRUS VACCINATION: AN ANALYSIS OF 13,665 PATIENTS OVER A 18-YEAR STUDY PERIOD
        : Giorgio Bogani (Italy)

09:20  IMPLEMENTATION OF AN ENHANCED RECOVERY AFTER SURGERY (ERAS) PROGRAM: THE MD ANDERSON CANCER CENTER EXPERIENCE
        : Pedro Ramirez (USA)

PLENARY: KEYNOTE LECTURE 1 - RANKL –BONES, SEX, AND BREAST CANCER

09:30 - 10:00  Hall A

RANKL -BONES, SEX, AND BREAST CANCER
Josef Penninger (Austria)

PLENARY: KEYNOTE LECTURE 2 -WHY ARE WE FAILING TO CURE OVARIAN CANCER?

10:00 - 10:30  Hall A

WHY ARE WE FAILING TO CURE OVARIAN CANCER?"
Christian Marth (Austria)

STATE OF THE ART: ENDOMETRIAL CANCER IN YOUNG WOMEN: NEW CHALLENGES

11:00 - 12:30  Hall A

Chair: Vesna Ksice (Serbia)
Chair: Dimitrios Haidopoulos (Greece)

11:00  RISK FACTORS AND PATHOGENESIS OF ENDOMETRIAL CANCER IN YOUNG WOMEN
Vesna Kesic (Serbia)
11:20  RADICAL TREATMENT OF ENDOMETRIAL CANCER IN YOUNG WOMEN
Nicoletta Colombo (Italy)
11:40  CONSERVATIVE TREATMENT OF ENDOMETRIAL CANCER IN YOUNG WOMEN
Dimitrios Haidopoulos (Greece)
12:00  MANAGEMENT OF RECURRENT DISEASE
Frederic Amant (The Netherlands)
12:20  DISCUSSION

PARALLEL: CURRENT STATUS OF IMMUNOTHERAPY
11:00 - 12:30  Hall B

Chair: Jonathan Ledermann (United Kingdom)
Chair: Christian Marth (Austria)
11:00  PRINCIPLES OF IMMUNOTHERAPY
Christian Marth (Austria)
11:20  CHALLENGES OF IMMUNOTHERAPY: PREDICTIVE FACTORS AND RESPONSE CRITERIA
Francis Balkwill (United Kingdom)
11:40  OVARIAN CANCER IMMUNOTHERAPY TRIALS
Jonathan Ledermann (United Kingdom)
12:00  CERVICAL CANCER IMMUNOTHERAPY TRIAL
Hans Nijman (The Netherlands)
12:20  DISCUSSION

DEBATE: DEBATES ON HOT TOPICS IN CERVICAL CANCER SURGERY
11:00 - 12:30  Hall C

Chair: Denis Querleu (France)
Chair: Nadeem Abu Rustum (USA)
Chair: Neville Hacker (Australia)
11:00  RADICAL VAGINAL SURGERY, MUSEUM OR OPERATING ROOM?
11:00  ABDOMINAL
Nadeem Abu Rustum (USA)
11:10  VAGINAL
Patrice Mathevet (France)
11:20  DISCUSSION
11:30  TMMR, THEORY OR PRACTICE ?
11:30  PRO
Rainer Kimmig (Germany)
11:40  CON
David Cibula (Czech Republic)
11:50  DISCUSSION
12:00  NERVE SPARING TECHNIQUES,: ROUTINE OR TAILORED ?
12:00  ROUTINE
Francesco Raspagliesi (Italy)
12:10  **TAILORED**
Eric Leblanc (France)

12:20  **DISCUSSION**

**PARALLEL: PHARMACO ECONOMICS: COST BENEFIT OF MODERN TREATMENT**

11:00 - 12:30  Hall M

Chair: Heinz Koelbl (Austria)
Chair: Richard Sullivan (United Kingdom)

11:00  **HOW CAN EMERGING ECONOMIES DELIVER AFFORDABLE AND EQUITABLE CANCER CARE FOR WOMEN?**
Richard Sullivan (United Kingdom)

11:20  Bengt Jonsson (Sweden)

11:40  **ECONOMIC IMPACT AND REIMBURSEMENT OF DEBULKING SURGERY**
Heinz Koelbl (Austria)

12:00  **COST-EFFICIENCY OF ROBOTIC COMPARED TO LAPAROSCOPIC APPROACHES IN GYNECOLOGIC ONCOLOGY**
Jordi Ponce (Spain)

12:20  **DISCUSSION**

**ENYGO SESSION: MY MISTAKE: REFLECTIONS ON HANDLING A MEDICAL MISTAKE**

12:30 - 14:00  ENYGO LOUNGE

12:30  **MY MISTAKE: REFLECTIONS ON HANDLING A MEDICAL MISTAKE**
Andreas Obermair (Australia)

**POSTER TALKS: POSTER TALK 2**

12:40 - 13:35  Exhibition Area

Chair: Charlie Gourley (United Kingdom)
Chair: Luis Chiva (Spain)

12:40  **DEVELOPMENT OF AN ANTIBODY MEDIATED OPTICAL IMAGING METHODOLOGY IN MOUSE MODELS OF HIGH-GRADE SEROUS OVARIAN CARCINOMA**
K. Bischof, M. Popa, I. Karlsen, K. Kleinmanns, S. Anandan, B.T. Gjertsen, L. Bjørgøe, E. McCormack (Norway)

12:45  **CHARACTERISTICS OF OVARIAN CANCER IN WOMEN WITH LYNCH SYNDROME**

12:50  **BORDERLINE OVARIAN TUMORS: A NATIONWIDE OVERVIEW OF INCIDENCE, SURVIVAL AND RISK OF SUBSEQUENT INVASIVE OVARIAN TUMORS**
M. Schuurman, M. Timmermans, K. Van de Vijver, T. Van Gorp, R. Kruitwagen, M. Van der Aa, V. Lemmens (The Netherlands)
12:55 - SURGICAL MORBIDITY OF ROBOTIC-ASSISTED SENTINEL LYMPH NODE BIOPSY VS. SYSTEMATIC PELVIC LYMPHADENECTOMY FOR ENDOMETRIAL CANCER STAGING: A PROPENSITY-MATCHED ANALYSIS

13:00 - OVARIAN PROTECTION AND FERTILITY PRESERVATION IN WOMEN WITH CANCER: A FRENCH REGISTRY ANALYSIS BETWEEN 2005 AND 2014.
M. Koskas, J. Philippeau (France)

13:05 - THE TEN YEAR EXPERIENCE OF A REGIONAL SPECIALIST GYNAECOLOGY CANCER GENETICS CLINIC WITH LYNCH SYNDROME

13:10 - RISK FACTORS FOR PARA-AORTIC LYMPH NODE METASTASIS IN ENDOMETRIAL CANCER
M.E. Sari, I. Yalcin, H. Sahin, M.M. Meydanli, T. Gungor (Turkey)

13:15 - IMPACT OF HORMONAL RECEPTOR STATUS AND KI-67 EXPRESSION ON DISEASE FREE SURVIVAL IN PATIENTS AFFECTED BY HIGH-RISK ENDOMETRIAL CANCER
V. Di Donato, V. Iacobelli, M. Schiavi, I. Pecorella, I. Palaia, C. Marchetti, A. Musella, F. Tomao, M. Monti, L. Muzii, L. Tramontano, P. Benedetti Panici (Italy)

13:20 - REDEFINING THE PRE-MALIGNANT LANDSCAPE OF GYNAECOLOGIC CANCERS: GENOMIC ANALYSIS OF UTERINE LAVAGE FLUID DETECTS BOTH EARLY STAGE CANCERS AND PRECANCEROUS CELLS OF UNKNOWN POTENTIAL.

13:25 - GENETICS OF ENDOMETRIAL CANCER IS GREATER THAN PREVIOUSLY ESTIMATED IN THE OUR LOCAL POPULATION.
A. Benshushan, N. Gazit, Y. Goldberg, T. Peretz, A. Zik (Israel)

13:30 - HIGH GRADE SEROUS OVARIAN CARCINOMAS ORIGINATE IN THE FALLOPIAN TUBE

INDUSTRY SESSION : SATELLITE SYMPOSIUM 6

13:00 - 14:30 Hall C

MEETING: ESGO BUSINESS MEETING

13:00 - 14:00 Hall M

STATE OF THE ART: RECENT HIGHLIGHTS ON OVARIAN CANCER

14:30 - 15:30 Hall A

Chair: Sandro Pignata (Italy)
PARALLEL: NEW END POINTS TO ASSESS THE IMPACT OF TREATMENT AND RELATED MORBIDITY ON OUTCOME

14:30 - 15:30  Hall B

Chair: Remi Nout (The Netherlands)
Chair: Lonneke Van de Poll-Franse (The Netherlands)

14:30  OVERVIEW OF CURRENT DEVELOPMENTS IN MEASURING AND REPORTING PATIENT REPORTED OUTCOMES AND QUALITY OF LIFE IN GYNAECOLOGICAL CANCER
Lonneke Van de Poll-Franse (The Netherlands)

14:50  HOW TO INTEGRATE PATIENT REPORTED OUTCOME TOOLS IN THE EVERYDAY GYNAECOLOGICAL CANCER CLINIC
Galina Velikova (United Kingdom)

15:10  WHICH ROLE CAN PATIENT REPORTED OUTCOMES AND QUALITY OF LIFE HAVE IN CLINICAL TRIALS
Remi Nout (The Netherlands)

ORAL COMMUNICATION: ORAL 7 - DIAGNOSTICS AND PREVENTION

14:30 - 15:30  Hall C

Chair: Pauline Wimberger (Germany)
Chair: Stephan Polterauer (Austria)

14:30  LONG TERM RESULTS FROM RT3VIN: A MULTI-CENTRE, RANDOMISED, PHASE II TRIAL OF CIDOFOVIR OR IMIQUIMOD TREATMENT FOR VULVAL INTRAEPITHELIAL NEOPLASIA 3
Sadie Jones (United Kingdom)

14:40  THE ANALGESIC EFFICACY OF FORCED COUGHING DURING CERVICAL PUNCH BIOPSY: A PROSPECTIVE RANDOMIZED CONTROLLED STUDY
Yakir Segev (Israel)

14:50  SENSITIVITY OF NON-INVASIVE PRENATAL FOR CANCER DETECTION AND TREATMENT MONITORING IN PREGNANT WOMEN
Liebeth Lenaerts, Ir, PhD (Belgium)

15:00  LONG-LASTING INCREASED RISK OF HPV-RELATED CARCINOMAS AND PREMALIGNANCIES AFTER CERVICAL INTRAEPITHELIAL NEOPLASIA GRADE 3: A POPULATION-BASED COHORT STUDY
Renee Ebisch (The Netherlands)

15:10  CARDIOVASCULAR RISK AFTER RISK-REDUCING SALPINGO-OOPHORECTOMY IN BRCA1/2 MUTATION CARRIERS: CARSOBRA STUDY
Marieke Arts-de Jong (The Netherlands)

15:20  LONG-TERM EFFICACY AND IMMUNOGENICITY OF THE 9-VALENT HUMAN PAPILLOMAVIRUS VACCINE: FINAL ANALYSES OF A DOUBLE-BLIND,
RANDOMIZED CLINICAL STUDY
: Elmar Joura (Austria)

TASK FORCE: ENITEC AS A FACILITATOR OF ENDOMETRIAL CANCER RESEARCH
14:30 - 15:30 Hall M

Chair: Frederic Amant (The Netherlands)
Chair: Erica Werner ()
14:30 CURETTAGE SPECIMEN GENOTYPING IDENTIFIES HIGH-RISK PATIENTS IN ENDOMETRIAL CANCER
Henrica Werner (Norway)
14:45 PROGNOSTIC MARKERS INCLUDING L1CAM EXPRESSION IN ENDOMETRIAL CARCINOMAS: AN ENITEC COLLABORATION STUDY
Hannie Pijnenborg (The Netherlands)
15:00 REFINING THE TCGA CLASSIFICATION OF ENDOMETRIAL CANCER
Tjalling Bosse (The Netherlands)
15:15 DISCUSSION : TBC ()

INDUSTRY SESSION : SATELLITE SYMPOSIUM 7
16:00 - 17:00 Hall B

INDUSTRY SESSION : SATELLITE SYMPOSIUM 8
16:00 - 17:00 Hall C

PARALLEL: HEREDITARY BREAST, OVARIAN & UTERINE CANCER
17:00 - 18:00 Hall A

Chair: Pauline Wimberger (Germany)
Chair: Uzi Beller (Israel)
17:00 CURRENT CLINICALLY MEANINGFUL ASPECTS AND IMPORTANCE OF GERMLINE AND SOMATIC MUTATIONS IN HEREDITARY BREAST CANCER
Jan Lubinski (Poland)
17:20 CURRENT CLINICALLY MEANINGFUL ASPECTS AND IMPORTANCE OF GERMLINE AND SOMATIC MUTATIONS IN HEREDITARY OVARIAN CANCER
Pauline Wimberger (Germany)
17:40 CURRENT CLINICALLY MEANINGFUL ASPECTS IN HEREDITARY UTERINE CANCER INCLUDING LYNCH SYNDROME
Uzi Beller (Israel)
PARALLEL: FUTURE DEVELOPMENT IN CLINICAL TRIALS

17:00 - 18:00
Hall B

Chair: Andreas Du Bois (Germany)
Chair: Andres Poveda (Spain)

17:00
SURGICAL TRAILS
Andreas Du Bois (Germany)

17:20
THE PARP-I STORY
Andres Poveda (Spain)

17:40
THE IMMUNOTHERAPY STORY
Lana Kandalaft (Switzerland)

AFFILIATED: ESP ESGO:CERVICAL PRECANCER: POST-TREATMENT DISEASE

17:00 - 18:00
Hall C

Chair: Vesna Kesic (Serbia)
Chair: Maria-Rosaria Raspollini (Italy)

17:00
INTRODUCTION: RISK FACTORS FOR POST-TREATMENT DISEASE
Vesna Kesic (Serbia)

17:00
INTRODUCTION: RISK FACTORS FOR POST-TREATMENT DISEASE
Maria-Rosaria Raspollini (Italy)

17:06
ESGO CLINICIAN: CLINICAL SIGNIFICANCE OF THE MARGINAL STATUS OF THE
EXCISED CONE: EFC QUALITY INDICATORS FOR COLPOSCOPY
Charles Redman (United Kingdom)

17:24
GUIDELINE ON HOW TO ASSESS THE CONE EXCISED TO TREAT CERVICAL
PRECANCER: WHAT NEEDS TO BE UPDATED IN EUROPEAN GUIDELINES ON
MANAGEMENT OF CERVICAL LESIONS
Sigurd Lax (Austria)

17:42
ESGO CLINICIAN IMPACT OF EXCISIONAL TREATMENT OF CERVICAL PRECANCER
ON FERTILITY: A BALANCE BETWEEN ONCOLOGICAL EFFECTIVENESS AND
OBSTETRICAL SAFETY
Maria Kyrgiou (United Kingdom)

ORAL COMMUNICATION: ORAL 8 - QUALITY OF LIFE

17:00 - 18:00
Hall M

Chair: Elisabeth Avall-Lundqvist (Sweden)
Chair: Kathrin Kirchheiner (Austria)

17:00
DEVELOPMENT AND PRE-TESTING OF THE EORTC QUALITY OF LIFE
QUESTIONNAIRE FOR VULVA CANCER PATIENTS – THE SIGNIFICANCE OF
PATIENT INVOLVEMENT
Pernille Jensen, Senior Consultant (Denmark)
### 17:10 Prediction Model for 30-Day Morbidity After Gynecological Malignancy Surgery
: Su hyun Chae (Republic of Korea)

### 17:20 Assessing Patient Reported Quality of Life Outcomes in Vulva Cancer Patients – A Systematic Literature Review
: Ligita Paskeviciute Frøding (Denmark)

### 17:30 Prospective Clinical Cohort Study for Efficacy Assessment of Topical Treatment with Olivoleina on Post-Surgical Scars in Patients Undergoing Radiotherapy for Gynecologic Cancers
: Jesús Molero Vílchez (Spain)

### 17:40 The Association of Lymphedema Trajectories with Symptoms and Symptom Severity Following Gynaecological Cancer Treatment in Queensland: A Prospective Cohort Study
: Andreas Obermair (Australia)

### 17:50 The New Nomal: Sexual Function After Ovarian Cancer for Survivors and Partners Compared to Normdata
: M.Caroline Vos, MSc (The Netherlands)

---

**Tumor Board: Tumor Board: Ovarian Cancer**

**18:00 - 19:00**  
Hall A

Chair: Philipp Harter (Germany)  
Chair: Cristiana Sessa (Switzerland)

**18:00** Surgical Management in Primary Ovarian Cancer  
Giovanni Aletti (Italy)

**18:15** Recurrent Ovarian Cancer - Role of Surgery  
Philipp Harter (Germany)

**18:30** Platinum Eligible Recurrent Ovarian Cancer  
Cristiana Sessa (Switzerland)

**18:45** Discussion

---

**Tumor Board: Tumor Board Cervical Cancer: Early Stage Positive Nodes**

**18:00 - 19:00**  
Hall B

Chair: Remi Nout (The Netherlands)  
Chair: Alexander Reinthaller (Austria)

**18:00** Cervical Cancer Stage IB1, 3CM Tumor Diameter: Evaluation of Lymph Nodes, Risk Factors and Therapeutic Management  
Remi Nout (The Netherlands)

**18:20** Cervical Cancer IB1, 2CM Tumor Diameter: SLN Biopsy, Management in regard to Absence/Presence of Metastatic Disease  
Alexander Reinthaller (Austria)

**18:40** Cervical Adenocarcinoma IB1 After Radical Hysterectomy, Positive Lymphnodes - Evaluation of Periaortic Nodes, Adjuvant Therapy, Management of Ovaries  
Sébastien Gouy (France)
TUMOR BOARD: TUMOR BOARD ENDO METRIAL CANCER: ADVANCED STAGE

18:00 - 19:00  Hall C

Chair: Melanie Powell (United Kingdom)
Chair: Guenter Emons (Germany)

18:00  CASE 1: ADVANCED ENDO METRIAL CANCER, AMENABLE TO SURGICAL RESECTION, ROLE OF NEO ADJUVANT CHEMOTHERAPY
Frederic Amant (The Netherlands)

18:20  CASE 2: ADVANCED, METASTATIC, TREATMENT WITH RADIOTHERAPY AND CHEMOTHERAPY
Melanie Powell (United Kingdom)

18:40  CASE 3: DISTANT METASTASES, ENDO CRINE THERAPY, CHEMOTHERAPY
Guenter Emons (Germany)

TUMOR BOARD: TUMOR BOARD: OBESITY

18:00 - 19:00  Hall M

Chair: Andreas Obermair (Australia)
Chair: Emma Crosbie (United Kingdom)

18:00  SURGERY (TO DISCUSS RELATIVE MERITS OF ROBOTIC, STRAIGHT STICK LAPAROSCOPY, LAPAROTOMY, VAGINAL Hysterectomy AND HYS TERCOTOMY PLUS PANNICULECTOMY/APRONECTOMY, PRE-, INTRA- AND POST-OP CONCERNS INCLUDING ANAESTHETIC ISSUES
Jason Wright (USA)

18:15  RADIOTHERAPY (WITH CURATIVE OR PALLIATIVE INTENT, THE CONSIDERATIONS FOR OBSE IN S, MODE OF DELIVERY, CURE RATES)
Carien Creutzberg (The Netherlands)

18:30  MIRENA (TO DISCUSS SUCCESS RATES, MIRENA VS MPA, FEMME TRIAL, PROS AND CONS, RELAPSE RATES, PREGNANCY RATES
Andreas Obermair (Australia)

18:45  BARIATRIC SURGERY/MIRENA (TO DISCUSS PROS/CONS IN CONTEXT OF TREATMENT OF DISEASE, REDUCING RISK OF RECURRENCE, PREGNANCY RATES, FITNESS FOR HYSTERECTOMY, LONG TERM HEALTH
Emma Crosbie (United Kingdom)

GLASS WITH EXPERT: GLASS WITH THE EXPERT 1

18:00 - 19:00  Hall E

18:00  MANAGEMENT OF STAGE IB2 CERVICAL CANCER
Neville Hacker (Australia)

18:00  MOLECULAR CLASSIFICATIONS OF ENDO METRIAL CANCERS
Tjalling Bosse (The Netherlands)
18:00 HISTOLOGICAL AND MOLECULAR CLASSIFICATION OF EPITHELIAL OVARIAN CANCER
Sigurd Lax (Austria)

18:00 SLN ALGORITHM ALONE IN STAGE I CERVICAL CANCER
Nadeem Abu Rustum (USA)

18:00 HIPEC IN OVARIAN CANCER
Giovanni Scambia (Italy)

18:00 ROBOTIC SURGERY IN GYNAECOLOGICAL ONCOLOGY
Henrik Falconer (Sweden)

18:00 SURGICAL OR RADILOGICAL STAGING OF ADVANCED CERVICAL CANCER
Denis Querleu (France)

18:00 ANESTHESIOLOGIC MANAGEMENT AND PERIPERATIVE CARE IN DEBULKING SURGERY FOR OVARIAN CANCER
Stephanie Suria (France)

18:00 PREDICTIVE BIOMARKERS OF RESPONSE TO NACT IN OVARIAN CANCER
Alexandra Leary (France)

18:00 HOW TO IDENTIFY PATIENTS WHO BENEFIT FROM SURGERY OF RECURRENT OVARIAN CANCER
Andreas Du Bois (Germany)

18:00 PERSPECTIVES OF IMMUNOTHERAPY IN CERVICAL CANCER
Jonathan Ledermann (United Kingdom)

18:00 HOW TO PLAN BREAST RECONSTRUCTION?
Christine Solbach (Germany)

18:00 PREVENTION AND MANAGEMENT OF SIDE-EFFECTS OF RADIOTHERAPY IN GYNAECOLOGIC CANCER
Richard Poetter (Austria)

18:00 FSS IN ADVANCED STAGE GERM CELL TUMORS
Michael Seckl (United Kingdom)

18:00 CURRENT UPDATE IN THE MANAGEMENT OF SIDE-EFFECTS IN NEOADJUVANT CHEMOTHERAPY
Edgar Petru (Austria)

18:00 KEY ISSUES AND PITFALLS OF THE DEBULKING SURGERY IN THE UPPER PART OF THE ABDOMEN
Jalid Sehouli (Germany)

OFFSITE SESSION: SEXUALITY AND ONCOLOGY
20:00 - 22:00 Secession

Chair: Vesna Kesic (Serbia)

20:00 GUIDED TOUR
20:30 A WOMEN’S GUIDE TO SEXUALITY WITH AND AFTER CANCER
Annette Hasenburg (Germany)

21:15 THE IMPACT OF A GYN CANCER ON THE SEXUAL WELL-BEING OF THE PARTNER
Leen Aerts (Belgium)
PARALLEL: UPDATE ON SUPPORTIVE CARE

07:30 - 08:30  Hall C

Chair: Felix Hilpert (Germany)
Chair: Jørn Herrstedt (Denmark)

07:30  PERIOPERATIVE SUPPORTIVE CARE IN GYNECOLOGIC CANCER PATIENTS
       Felix Hilpert (Germany)

08:00  SUPPORTIVE CARE IN GYNECOLOGIC CANCER PATIENTS RECEIVING MEDICAL TREATMENT
       Jørn Herrstedt (Denmark)

08:30  SUPPORTIVE CARE FOR WOMEN WITH GYNAECOLOGIC CANCER RECEIVING EXTERNAL BEAM RADIOTHERAPY AND BRACHYTHERAPY
       Alina Sturdza (Austria)

WORKSHOP/SEMINAR: FELLOWS WORKSHOP

08:30 - 12:00  Hall N

08:30  OVARIAN CANCER
08:30  Chair: Stephan Polterauer (Austria)
08:30  Chair: Vladyslav Sukhin (Ukraine)
08:30  HOW TO SELECT PATIENTS FOR UPFRONT DEBULKING SURGERY (PET VS CT VS DIAGNOSTIC LAPAROSCOPY): PRESENTATION OF DIFFERENT APPROACHES/FEASIBILITY/DISCUSSION.
       Giovanni Aletti (Italy)
08:50  PARAAORTIC LYMPHADENECTOMY
       Ignacio Zapardiel Gutierrez (Spain)
09:00  PELVIC LYMPHADENECTOMY
       Michael Halaska (Czech Republic)
09:10  EXTRAPERITONEAL EN BLOC HYSTERECTOMY/OOPHORECTOMY/COLECTOMY
       Rene Laky (Austria)
09:25  EN BLOC SPLENECTOMY/OMENTECTOMY
       Giovanni Aletti (Italy)
09:40  DIAPHRAGM RESECTION (SANDWICH TECHNIQUE)
       Christoph Grimm (Austria)
09:50 PODIUMS DISCUSSION
10:30 COFFEE BREAK
11:00 PALLIATIVE CARE
11:00 Chair: David Lindquist (Sweden)
11:00 Chair: Polat Dursun (Turkey)
11:00 MANAGEMENT OF MALIGNANT BOWEL OBSTRUCTION - SURGERY?
Thomas Bachleitner (Austria)
11:15 MANAGEMENT OF MALIGNANT BOWEL OBSTRUCTION - CONSERVATIVE TREATMENT?
Edgar Petru (Austria)
11:30 PALLIATIVE RADIOTHERAPY - BENEFITS AND LIMITATIONS
Carien Creutzberg (The Netherlands)
11:45 PANEL DISCUSSION AND ROOM FOR QUESTIONS

PARALLEL: SURVIVORSHIP
07:30 - 08:30 Hall M

Chair: Elisabeth Avall-Lundqvist (Sweden)
Chair: Lonneke Van de Poll-Franse (The Netherlands)
07:30 LATE EFFECTS AND LONG TERM COMPLICATIONS OF CANCER THERAPY
Elisabeth Avall-Lundqvist (Sweden)
07:50 SYMPTOM MANAGEMENT OF LATE SIDE-EFFECTS AMONG GYNECOLOGICAL CANCER SURVIVORS
Heidi Donovan (USA)
08:10 WHAT IS NEEDED IN SURVIVORSHIP CARE
Lonneke Van de Poll-Franse (The Netherlands)

ORAL COMMUNICATION: ORAL 9 -OVARIAN AND CERVICAL CANCER
08:30 - 09:30 Hall B

Chair: Luis Chiva (Spain)
Chair: Jordi Ponce (Spain)
08:30 CONSERVATIVE SURGERY FOR THE TREATMENT OF GRANULOSA CELL TUMORS OF THE OVARY: RESULTS FROM THE MITO 9 STUDY
Alice Bergamini, dr (Italy)
08:40 PRETERM BIRTH AND CONIZATION PRIOR TO PREGNANCY: AN ANALYSIS OF THE NATIONAL INPATIENT QUALITY SURVEY DATA IN GERMANY; 2009-2014.
Christian Dannecker (Germany)
08:50 PROVE A PHASE II RANDOMIZED MULTICENTER STUDY OF PANITUMUMAB IN PLATINUM-SENSITIVE EPITHELIAL OVARIAN CANCER PATIENTS WITH KRAS WILD-TYPE
Radoslav Chekerov (Germany)
09:00 EFFECTIVENESS OF NATIONAL HUMAN PAPILLOMAVIRUS VACCINATION PROGRAM FOR JAPANESE YOUNG WOMEN
Yamaguchi Manako (Japan)
09:10  CLINICAL ANALYSIS OF ENDOMETRIOID AND CLEAR CELL CARCINOMA OF THE OVARY WITH OR WITHOUT ENDOMETRIOSIS  
: Uchul Ju (Republic of Korea)

09:20  COMPARISON OF MRI, PET-CT, AND FROZEN BIOPSY IN THE EVALUATION OF LYMPH NODE STATUS BEFORE FERTILITY-SPRING RADICAL TRACHELECTOMY IN EARLY STAGE CERVICAL CANCER  
: Jeong-Yeol Park (Republic of Korea)

PARALLEL: HISTORY OF GYNAECOLOGICAL ONCOLOGY IN AUSTRIA

08:30 - 09:30  
Hall C

Chair: Wolfgang Graninger (Austria)  
Chair: Karl Tamussino (Austria)

08:30  FROM SEMMELWEIS AND PUERPERAL SEPSIS TO MULTIRESISTANT BACTERIA: A HISTORY OF HOSPITAL INFECTION CONTROL  
: Wolfgang Graninger (Austria)

09:00  LIGHT AND DARKNESS: THE HISTORY OF GYNAE ONCOLOGY IN AUSTRIA  
: Karl Tamussino (Austria)

ORAL COMMUNICATION: ORAL 10 - ENDOMETRIAL II

08:30 - 09:30  
Hall M

Chair: Daniel Reimer (Austria)  
Chair: Frederic Goffin (Belgium)

08:30  EXPRESSION OF L1CAM IN CURETTAGE AND HIGH L1CAM LEVEL IN PREOPERATIVE BLOOD SAMPLES PREDICTS LYMPH NODE METASTASES AND POOR OUTCOME IN ENDOMETRIAL CANCER PATIENTS  
: Ingvild Loberg Tangen (Norway)

08:40  CIRCULATING CELL-FREE DNA IN ENDOMETRIAL CANCER.  
: Lucia Cicchillitti, Ph.D (Italy)

08:50  PROGNOSTIC BENEFIT OF POLE EXONUCLEASE DOMAIN MUTATIONS IN ENDOMETRIAL CANCER CANNOT BE EXPLAINED BY INCREASED SENSITIVITY TO ADJUVANT TREATMENT STRATEGIES  
: Inge Van Gool (The Netherlands)

09:00  POST-PREGNANCY OUTCOMES OF YOUNG PATIENTS WITH ENDOMETRIAL CANCER OR ATYPICAL ENDOMETRIAL HYPERPLASIA WHO RECEIVED FERTILITY-PRESERVING HORMONAL THERAPY USING MEDROXYPROGESTERONE ACETATE.  
: Nobuyuki Susumu (Japan)

09:10  A COMPARATIVE STUDY OF TWO FOLLOW-UP STRATEGIES FOLLOWING TREATMENT OF ENDOMETRIAL CANCER BETWEEN AN ITALIAN AND A UK CENTRE  
: Valentina Ghiardi (United Kingdom)

09:20  DOES THE NODAL RE-STAGING SURGERY FOR HIGH RISK ENDOMETRIAL CANCER, ACCORDING TO THE RECOMMENDATIONS OF THE ESMO-ESGO-ESTRO GUIDELINES, CHANGE THE MANAGEMENT OF PATIENTS?  
: Sébastien Gouy (France)

PARALLEL: MANAGEMENT OF GYNAECOLOGICAL CANCERS IN ELDERLY
09:30 - 10:30

Chair: Annamaria Ferrero (Italy)
Chair: Dina Kurdiani (Georgia)
09:30  **FRAILTY EVALUATION AND MEDICAL TREATMENT OF ELDERLY POPULATION WITH GYNAECOLOGICAL MALIGNANCIES**
Annamaria Ferrero (Italy)
09:50  **ELDERLY PATIENTS UNDERGOING SURGERY FOR OVARIAN OR CERVICAL CANCER: PERI-OPERATIVE ASSESSMENT AND SURGICAL CHOICES**
Dina Kurdiani (Georgia)
10:10  **LAPAROSCOPIC VERSUS OPEN TREATMENT OF ENDOMETRIAL CANCER IN ELDERLY WOMEN**
Ignacio Zapardiel Gultierrez (Spain)

PARALLEL: PREDICTIVE MARKERS IN GYNAE CANCERS

09:30 - 10:30

Chair: Alexandra Leary (France)
Chair: Xavier Matias Guiu (Spain)
09:30  **PREDICTIVE MARKERS IN ENDOMETRIAL CARCINOMA**
Xavier Matias Guiu (Spain)
09:50  **PREDICTIVE MARKERS IN OVARIAN CARCINOMA**
Alexandra Leary (France)
10:10  **PREDICTIVE MARKERS IN CERVICAL CANCER**
Tjalling Bosse (The Netherlands)

AFFILIATED: ESTRO - STATE OF THE ART TREATMENT OF VAGINAL CANCER

09:30 - 10:30

Chair: Remi Nout (The Netherlands)
Co-Chair: Richard Poetter (Austria)
09:30  **INTRODUCTION AND REVIEW OF TREATMENT FOR VAGINAL CANCER**
Remi Nout (The Netherlands)
09:50  **IMAGE GUIDED RADIOTHERAPY FOR VAGINAL CANCER**
Maximilian Schmid (Austria)
10:10  **RESULTS OF IMAGE GUIDED BRACHYTHERAPY AND FUTURE OUTLOOK**
Henrike Westerveld (The Netherlands)

PARALLEL: FOLLOW-UP OF STATE OF ART MEETING: PREVENTION GYNAECOLOGICAL CANCER, ANTALYA 2016

11:00 - 12:30
11:00  THE IMPACT OF HEALTHY LIFE STYLE AND OBESITY ON PREVENTION OF GYNAECOLOGICAL CANCERS
       Maria Kyrgiou (United Kingdom)
11:22  STATE OF ART IN SCREENING OF GYNAECOLOGICAL CANCERS
       Murat Gultekin (Turkey)
11:45  HEREDITARY GYNAECOLOGICAL CANCERS: PREVENTION AND ROLE OF PROPHYLACTIC SURGERIES
       Ranjit Manchanda (United Kingdom)
12:07  PSYCHO-SOCIAL ISSUES IN GYNAECOLOGICAL CANCER PREVENTION
       Vesna Kesic (Serbia)

STATE OF THE ART: UPDATES ON RARE GYNAECOLOGICAL CANCERS

11:00 - 12:30  Hall B

Chair: Michael Seckl (United Kingdom)
Chair: Isabelle Ray-Coquard (France)
11:00  RECENT DEVELOPMENTS IN GTD AND MOLAR PREGNANCIES
       Leon Massuger (The Netherlands)
11:22  HOW CAN WE ELIMINATE DEATHS IN HIGH RISK GTN?
       Michael Seckl (United Kingdom)
11:45  WHAT IS THE STATE-OF-THE-ART FOR OVARIAN GERM CELL TUMOURS?
       Jalid Sehouli (Germany)
12:07  CURRENT AND FUTURE DIRECTIONS FOR GRANULOSA CELL TUMOUR MANAGEMENT
       Isabelle Ray-Coquard (France)

PLENARY: CLOSING CEREMONY AND AWARDS

12:30 - 13:00  Hall B

Chair: Denis Querleu (France)
Chair: Heinz Koelbl (Austria)